scholarly journals Antimicrobial Susceptibilities of Group B Streptococci Isolated between 1992 and 1996 from Patients with Bacteremia or Meningitis

1998 ◽  
Vol 42 (6) ◽  
pp. 1517-1519 ◽  
Author(s):  
Marisol Fernandez ◽  
Melissa E. Hickman ◽  
Carol J. Baker
Keyword(s):  
Penicillin G ◽  
Group B Streptococci ◽  
Streptococcal Disease ◽  
Drug Of Choice ◽  
Treatment And Prevention ◽  
Invasive Infections ◽  
Group B Streptococcal Disease ◽  
Continued Use ◽  
Group B

ABSTRACT In vitro testing of 229 group B streptococcal isolates from a variety of patients with invasive infections indicated uniform penicillin G susceptibility. However, 17 (7.4%) isolates were resistant to erythromycin and 8 (3.4%) were resistant to clindamycin. These results support the continued use of penicillin G as the drug of choice for the treatment and prevention of group B streptococcal disease.

Erratum

1994 ◽  
Vol 15 (8) ◽  
pp. 310-310
Keyword(s):  
Penicillin G ◽  
Correct Treatment ◽  
Streptococcal Disease ◽  
Group B Streptococcal Disease ◽  
Group B

There is an incorrect dosage in the article Cervical Adenopathy that appeared in the July 1994 issue. In Table 10 on page 283, the correct treatment for documented group B streptococcal disease in infants having usual associated bacteremia is Aqueous penicillin G 200 000 IU/kg/day IV, if sensitive.

Group B β-Hemolytic Streptococcal Osteomyelitis in a Neonate

PEDIATRICS ◽  
1977 ◽  
Vol 59 (6) ◽  
pp. 1053-1054
Author(s):  
Kenneth C. Henderson ◽  
Reuben S. Roberts ◽  
Susan B. Dorsey
Keyword(s):  
Case Report ◽  
Late Onset ◽  
Orbital Cellulitis ◽  
Group B Streptococci ◽  
Streptococcal Disease ◽  
Serious Infection ◽  
Clinical Syndromes ◽  
Clinical Presentations ◽  
Group B Streptococcal Disease ◽  
Group B

Group B β-hemolytic streptococci have gained much attention in recent years as a cause of serious infection in the newborn. Two clinical syndromes have been defined as "early onset" fulminant septicemia and a "late onset" meningitis.1,2 Howard and McCracken,3 more recently, have documented some previously unrecognized clinical presentations of group B streptococcal disease. These include asymptomatic bacteremia, septic arthritis, osteomyelitis, ethmoiditis with orbital cellulitis, pneumonia with empyema, facial cellulitis, and conjunctivitis. The literature to date reports five instances of osteomyelitis due to group B streptococci as reported in four articles.3-6 This case report of group B streptococcal osteomyelitis is presented to emphasize the insidious nature of this infection in a neonate and the lack of systemic toxicity with which it occurs.

scholarly journals Trends in molecular characteristics and antimicrobial resistance of group B streptococci: a multicenter study in Serbia, 2015–2020

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Dusan Kekic ◽  
Ina Gajic ◽  
Natasa Opavski ◽  
Milan Kojic ◽  
Goran Vukotic ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Late Onset ◽  
Group B Streptococcus ◽  
Neonatal Morbidity ◽  
Disease Rate ◽  
Molecular Characteristics ◽  
Group B Streptococci ◽  
Live Births ◽  
Invasive Infections ◽  
Group B

AbstractGroup B Streptococcus (GBS) is a major cause of neonatal morbidity and mortality. Serbia has not fully implemented preventive measures against GBS neonatal diseases. Therefore, we aimed to assess the maternal GBS colonisation and invasive neonatal disease rate, to reveal the trends of antimicrobial resistance and serotype distribution of GBS from various patient groups. Randomly selected non-invasive (n = 991) and all invasive GBS (n = 80) collected throughout Serbia from 2015 to 2020 were tested for antimicrobial susceptibility, capsular typing, and hvgA detection. Overall, 877/5621 (15.6%) pregnant women were colonised with GBS. Invasive GBS infections incidence in infants (0.18/1000 live births) showed a decreasing trend (0.3 to 0.1/1000 live births). Type III was overrepresented in infants with invasive infections (n = 35, 58.3%), whereas type V predominated among colonised adults (n = 224, 25.5%) and those with noninvasive (n = 37, 32.5%) and invasive infections (n = 8, 40%). The hypervirulent clone III/ST17 was highly associated with invasive infections (n = 28, 35%), particularly late-onset disease (n = 9, 47.4%), showing an increase from 12.3 to 14.8%. The GBS resistance to erythromycin and clindamycin was 26.7% and 22.1%, respectively, with an upward trend. The emergence of the hypervirulent clone III/ST17 and the escalation in GBS resistance highlight an urgent need for continuous monitoring of GBS infections.

Intrapartum chemoprophylaxis of early-onset group B streptococcal disease

1991 ◽  
Vol 40 (1) ◽  
pp. 57-62 ◽  
Author(s):  
R. Matorras ◽  
A. García-Perea ◽  
F. Omeñaca ◽  
M. Diez-Enciso ◽  
R. Madero ◽  
...  
Keyword(s):  
Early Onset ◽  
Streptococcal Disease ◽  
Group B Streptococcal Disease ◽  
Group B ◽  
Onset Group ◽  
Early Onset Group
Sign in / Sign up

Export Citation Format

Share Document